About Cvergenx
Cvergenx is a Healthcare company based in Tampa (United States) founded in 2009. Diagnostic solutions for personalized radiation therapy in oncology are provided. Cvergenx has raised $615.55 thousand across 2 funding rounds. Cvergenx offers products and services including pGRT Platform, GARD, and RSI. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Pan Cancer. Its legal entity in India is Cvergenx Technologies India Private Limited (U85100KA2019FTC122596). Its competitors include GRAIL, Denali Therapeutics and Poseida Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2009 and based in Tampa, United States, CvergenX operates in the radiation oncology sector. Diagnostic tools are developed to support personalized medicine for cancer patients. The patented Radiosensitivity Index (RSI) is utilized by radiation oncologists to adjust treatment doses according to tumor genetics. Radiation planning and therapy are thereby optimized through these genetic-based adaptations.
- Headquarters Tampa, United States
- SectorsHealthcare
- Website cvergenx.com
- Social LinkedIn
- Legal Name Cvergenx Technologies India Private Limited
- Date of Incorporation 22 Mar, 2019
- Jurisdiction Bangalore, Karnataka, India
- Indian entity net loss-₹59,968
FY 2020 · 0% margin
- Indian entity EBITDA-₹59,968
FY 2020 · 0% margin
- Total Equity Funding$615.55K (USD)
in 2 rounds
- Latest Funding Round$390K (USD), Seed
Dec 2015
Associated legal entities of Cvergenx
Cvergenx operates through Cvergenx Technologies India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2020) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Cvergenx Technologies India Private Limited CIN U85100KA2019FTC122596 | Active | 22 Mar 2019 | Bangalore, Karnataka | 2 | View details |
Products & Services of Cvergenx
Cvergenx offers a comprehensive portfolio of products and services, including pGRT Platform, GARD, and RSI.
Uses genomic data to optimize radiation therapy doses for individual patients
Quantifies personalized radiation effects based on tumor biology
Measures tumor response to radiation for treatment planning
Funding Insights of Cvergenx
Cvergenx has successfully raised a total of $615.55K across 2 strategic funding rounds. The most recent funding activity was a Seed round of $390 thousand completed in December 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $615,554
- Total Rounds 2
- Last Round Seed — $390,000
- First Round $225,554
(Apr 2010)
All 2 funding rounds of Cvergenx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2015 | $390,000 | Seed | – | – | – |
| Apr 2010 | $225,554 | Seed | – | – | – |
Board of directors of Cvergenx Technologies India Private Limited (Cvergenx)
Cvergenx Technologies India Private Limited is the primary company behind Cvergenx. The board of Cvergenx Technologies India Private Limited currently have 2 directors; the longest-serving is Raymond F Vennare, appointed in 2019. 1 earlier director has ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Raymond F Vennare DIN 08396779 | Director | 22 Mar 2019 | 7 yrs 7 mo | Cvergenx Technologies India Private Limited |
| Gopala Reddy Lohith DIN 08992053 | Additional Director | 10 Dec 2020 | 5 yrs 10 mo | Cvergenx Technologies India Private Limited |
People of Cvergenx
6 people are tracked at Cvergenx (3 in leadership, 3 in board & advisors).
| Name | Role | Group |
|---|---|---|
Steven A. Eschrich | Co-Founder & CTO | Leadership |
Javier F. Torres-Roca | Co-Founder & Acting CEO | Leadership |
Jacob G. Scott | Co-Founder & CSO | Leadership |
John G. Kokales | Director | Board & advisors |
| Chairman | Board & advisors | |
David S. Smith | Director | Board & advisors |
Complete people profiles for Cvergenx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Cvergenx
Figures of Cvergenx Technologies India Private Limited, the primary company behind Cvergenx, for FY 2020. Net loss was -₹59,968 (0% margin). EBITDA was -₹59,968 (0% margin).
- -₹59,968Net loss · 0% margin
- -₹59,968EBITDA · 0% margin
- ₹1 LakhPaid-up capital
Balance sheet, profit and loss, cash flow and ratios of Cvergenx Technologies India Private Limited are on its company page.
Detailed financial statements for Cvergenx
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Cvergenx
3 dated milestones of Cvergenx across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Cvergenx is founded.
- Funding First funding round of $226K.
- Funding Latest funding round, Seed, of $390K.
Competitors of Cvergenx
Cvergenx has 3 listed competitors in our database, 3 of them funded. They include GRAIL, Denali Therapeutics and Poseida Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| grail.com | 2016 | Menlo Park, United States | $2B | 491 | Circulating tumor DNA is screened for early cancer detection. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies |
Detailed competitors of Cvergenx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Cvergenx (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cvergenx
Complete news archive for Cvergenx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cvergenx
Cvergenx was founded in 2009 and raised its 1st funding round 1 year after it was founded.
Cvergenx is headquartered in Tampa, United States. It is registered at Tampa, Florida, United States.
Cvergenx is a funded company, having raised a total of $615.55K across 2 funding rounds to date. The company's 1st funding round was a Seed of $225.55K, raised on Apr 2010.
Founded in 2009 and based in Tampa, United States, CvergenX operates in the radiation oncology sector. Diagnostic tools are developed to support personalized medicine for cancer patients. The patented Radiosensitivity Index (RSI) is utilized by radiation oncologists to adjust treatment doses according to tumor genetics. Radiation planning and therapy are thereby optimized through these genetic-based adaptations.
Cvergenx's top competitors include GRAIL, Poseida Therapeutics and Denali Therapeutics.
Cvergenx offers pGRT Platform, GARD, and RSI.
Cvergenx operates through Cvergenx Technologies India Private Limited.
The legal entities of Cvergenx currently have 2 directors, including Gopala Reddy Lohith, Raymond F Vennare.